{"cluster": 36, "subcluster": 15, "abstract_summ": "The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), interleukines (IL), tumor necrosis factor (TNF)-\u03b1) and chemokines.2-3 So, some Chinese researchers proposed or used anti-inflammatory agents in the treatment regimen of patients with COVID-19.3-4.In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).National and international registries are being created to collect data on rheumatic patients with CoViD-19.Currently, the world is facing the pandemic of a novel strain of beta\u2010coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102).However, previous studies on corticosteroid therapy in severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus illustrated delayed viral clearance, with no survival benefit and perhaps even adverse outcomes.2 Some patients with COVID-19 exhibit biphasic disease evolution with a mild presentation followed by a secondary respiratory deterioration due to a cytokine storm, despite decreasing viral load.2 Therefore, timing of corticosteroid therapy might be particularly consequential, with early administration reducing inflammatory response and viral clearance during the initial phase.Altogether, we highly recommend clinicians to look after those antibiotics with anti-inflammatory activity for both empiric antibiotic therapy and reducing the inflammation to prevent septic shock in patients with diagnosed COVID-19.Current coronavirus pandemic named coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress among patients with COVID-19.", "title_summ": "Beyond the anti-viral therapy: A comprehensive reviewCOVID-19 infection and rheumatoid arthritis: Faraway, so close!The CoV-2 outbreak: how hematologists could help to fight Covid-19The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19Why tocilizumab could be an effective treatment for severe COVID-19?A review for natural polysaccharides with anti-pulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoVCytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and AutoimmunityConsideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint InhibitorsTreatment of COVID-19-exacerbated asthma: should systemic corticosteroids be used?COVID-19 and MS disease-modifying therapiesThe use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from ChinaTowards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroidsA potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2Adjunct immunotherapies for the management of severely ill COVID-19 patientsRecommendations for coronavirus infection in rheumatic diseases treated with biologic therapyA Comprehensive Review on Tocilizumab in COVID\u201019 Acute Respiratory Distress SyndromeThe added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?Anakinra for severe forms of COVID-19: a cohort studyEmerging Trends in COVID-19 Treatment: Learning from Inflammatory Conditions Associated with Cellular TherapiesLow dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS)COVID-19 and lung cancer: risks, mechanisms and treatment interactionsCOVID-19 and immune checkpoint inhibitors: initial considerationsTwo known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19No indications for overt innate immune suppression in critically ill COVID-19 patientsMetronidazole; a Potential Novel Addition to the COVID-19 Treatment RegimenInappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus-19 Disease (COVID-19)Considerations for Statin Therapy in Patients with COVID\u201019Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapyCan pioglitazone be potentially useful therapeutically in treating patients with covid-19?Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case reportPersistent Viral Presence Determines the Clinical Course of the Disease in COVID-19Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19Antenatal corticosteroid therapy and COVID\u201019: Pathophysiological considerationsA critical evaluation of glucocorticoids in the treatment of severe COVID-19Immunomodulatory therapy for the management of severe COVID-19.Anti-cytokine therapy in novel coronavirus disease (COVID-19) \u2013 the first administration of tocilizumab in Hungary at a department of infectologyClinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.Nebulized Lidocaine in COVID-19, An Hypothesis.Not so fast.", "title_abstract_phrases": "The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), interleukines (IL), tumor necrosis factor (TNF)-\u03b1) and chemokines.2-3 So, some Chinese researchers proposed or used anti-inflammatory agents in the treatment regimen of patients with COVID-19.3-4.Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapyIn December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).National and international registries are being created to collect data on rheumatic patients with CoViD-19.A Comprehensive Review on Tocilizumab in COVID\u201019 Acute Respiratory Distress SyndromeCurrently, the world is facing the pandemic of a novel strain of beta\u2010coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102).However, previous studies on corticosteroid therapy in severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus illustrated delayed viral clearance, with no survival benefit and perhaps even adverse outcomes.2 Some patients with COVID-19 exhibit biphasic disease evolution with a mild presentation followed by a secondary respiratory deterioration due to a cytokine storm, despite decreasing viral load.2 Therefore, timing of corticosteroid therapy might be particularly consequential, with early administration reducing inflammatory response and viral clearance during the initial phase.It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress among patients with COVID-19.Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS)The new coronavirus COVID-19 disease caused by SARS-CoV-2 was declared as global public health emergency by WHO on Jan 30, 2020."}